共 20 条
- [1] Portaccio E(2011)Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis Core Evid 6 13-21
- [2] Aktas O(2010)Fingolimod is a potential novel therapy for multiple sclerosis Nat Rev Neurol 6 373-382
- [3] Kury P(2011)New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate J Am Pharm Assoc 51 122-126
- [4] Kieseier B(2010)Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 402-415
- [5] Hartung H-P(2013)Study of aqueous phase aggregation of FTY720 (fingolimod hydrochloride) and its effect on DMPC liposomes using fluorescent molecular probes Phys Chem Chem Phys 15 17962-17970
- [6] Hussar DA(2006)Synthesis of fingolimod Chin J New Drugs 15 802-804
- [7] Zimmerman DE(2005)UPLC; an introduction and review J Liq Chromatogr RT 28 1253-1263
- [8] Cohen JA(2006)Use of ultra-performance liquid chromatography in pharmaceutical development J Chromatogr A 140 1119-767
- [9] Swain J(2001)Validation in pharmaceutical analysis, part 1: an integrated approach J Pharm Biomed Anal 24 755-870
- [10] Mohapatra M(2005)Validation in pharmaceutical analysis, part II; Central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data J Pharm Biomed Anal 37 859-undefined